Glofitamab Clinical Trials
34 recruitingDrug
Phase 222Phase 111Phase 31Early Phase 11
Showing 1–20 of 34 trials
Recruiting
Phase 2
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
B-Cell Non-Hodgkins Lymphoma
Hoffmann-La Roche100 enrolled53 locationsNCT06806033
Recruiting
Phase 2
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
RituximabMCLBTKi+2 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT07257055
Recruiting
Phase 2
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
National Cancer Institute (NCI)20 enrolled6 locationsNCT07003295
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1Phase 2
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Mature B-cell Non-Hodgkin Lymphoma
Hoffmann-La Roche65 enrolled29 locationsNCT05533775
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Hoffmann-La Roche300 enrolled17 locationsNCT07200375
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Lymphoma
Hoffmann-La Roche50 enrolled16 locationsNCT06624085
Recruiting
Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Lymphoma
Hoffmann-La Roche182 enrolled76 locationsNCT06084936
Recruiting
Phase 2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center42 enrolled7 locationsNCT06765317
Recruiting
Phase 2
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
University of California, San Francisco30 enrolled3 locationsNCT06252675
Recruiting
Phase 1Phase 2
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Hoffmann-La Roche940 enrolled38 locationsNCT03075696
Recruiting
Glofitamab in Chinese Patients With R/R DLBCL
DLBCL - Diffuse Large B Cell Lymphoma
Peking Union Medical College Hospital20 enrolled1 locationNCT06481826
Recruiting
Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
B-cell Non Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
ADC Therapeutics S.A.200 enrolled42 locationsNCT04970901
Recruiting
Phase 1
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Mantle Cell LymphomaMCL
Memorial Sloan Kettering Cancer Center39 enrolled10 locationsNCT06192888
Recruiting
Phase 2
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
MCLRelapsed or Refractory Mantle Cell Lymphoma (MCL)
Peking University Third Hospital43 enrolled1 locationNCT07460362
Recruiting
Phase 2
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
LymphomaLymphoma, Large B-Cell, Diffuse
Jennifer Crombie, MD41 enrolled3 locationsNCT05800366
Recruiting
Phase 1
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B Cell Lymphoma+6 more
University of Washington56 enrolled1 locationNCT04231877
Recruiting
Phase 1Phase 2
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Mantle Cell LymphomaBlastoid Variant Mantle Cell LymphomaPleomorphic Variant Mantle Cell Lymphoma
City of Hope Medical Center50 enrolled2 locationsNCT05861050
Recruiting
Phase 2
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
Lymphoma, Mantle-Cell
The Lymphoma Academic Research Organisation100 enrolled16 locationsNCT06558604
Recruiting
Phase 1
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.255 enrolled17 locationsNCT06393738